News from Teiko

Teiko is excited to announce that two posters have been accepted for presentation at the 2024 Society for Immunotherapy of Cancer (SITC) annual meeting in Houston from November 8 – 10th.

Teiko accepts two posters at the International Clinical Cytometry Conferences (ICCS) in Seattle. On Monday, October 7, two poster presentations will take place regarding assessing normalization methods for CyTOF data and analyzing fixed whole blood samples by high-dimensional spectral cytometry.

Introducing our new feature, Dynamic Baseline, now available on app.teiko.bio. This feature allows users to set any time point, such as the start of lymphodepletion (e.g., C1D15), as the new baseline for normalization, providing more flexibility when analyzing longitudinal data across key clinical milestones.

The StandardPlus service lets customers add an additional antibody to Teiko’s Standard 41-marker peripheral blood mononuclear cell (PBMC) or whole blood (WB) mass cytometry (CyTOF) panel to detect a specific marker of interest. Drug developers often need to track a specific cell type, target, pathway, or a general marker of interest in their clinical trials. Now, with Teiko, it’s simple. You pick an antibody, and we verify that antibody on a CLIA-validated backbone.

Ordering and tracking specimen collection kits have been challenging due to the reliance on manual emails and spreadsheets. We are excited to announce the launch of our new online ordering system for TokuKits: kits.teiko.bio. A simple shopping platform to order sample collection TokuKits for clinical trials. When an order is placed on kits.teiko.bio, it is immediately registered in Teiko’s Laboratory Information Management System (LIMS), allowing us to prompty contact the trial site that placed the order.